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Abstract
Background: The PALB2 gene, also known as FANCN, forms a bond and co-localizes with BRCA2 in DNA repair. Germline
mutations in PALB2 have been identified in approximately 1% of familial breast cancer and 3–4% of familial pancreatic
cancer. The goal of this study was to determine the prevalence of PALB2 mutations in a population of BRCA1/BRCA2
negative breast cancer patients selected from either a personal or family history of pancreatic cancer.
Methods: 132 non-BRCA1/BRCA2 breast/ovarian cancer families with at least one pancreatic cancer case were included in
the study. PALB2 mutational analysis was performed by direct sequencing of all coding exons and intron/exon boundaries,
as well as multiplex ligation-dependent probe amplification.
Results: Two PALB2 truncating mutations, the c.1653T.A (p.Tyr551Stop) previously reported, and c.3362del
(p.Gly1121ValfsX3) which is a novel frameshift mutation, were identified. Moreover, several PALB2 variants were detected;
some of them were predicted as pathological by bioinformatic analysis. Considering truncating mutations, the prevalence
rate of our population of BRCA1/2-negative breast cancer patients with pancreatic cancer is 1.5%.
Conclusions: The prevalence rate of PALB2 mutations in non-BRCA1/BRCA2 breast/ovarian cancer families, selected from
either a personal or family pancreatic cancer history, is similar to that previously described for unselected breast/ovarian
cancer families. Future research directed towards identifying other gene(s) involved in the development of breast/
pancreatic cancer families is required.
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Introduction
Hereditary breast cancer accounts for approximately 5–10% of
all breast cancer cases. Mutations in the two main susceptibility
genes BRCA1 and BRCA2, together with mutations in a number of
other high-penetrance genes such as TP53 and PTEN, account for
20% of familial breast cancer cases [1]–[3]. For the remaining
80%, the genetic factors are largely unknown and they are likely to
involve mutations in moderate and low penetrance susceptibility
genes, plausibly acting together with some environmental or other
hereditary factors. Apart from breast and ovarian cancer, BRCA1
and BRCA2 carriers might be at higher risk for additional
malignancies such as prostate, colorectal, familial melanoma and
pancreatic cancers.
Pancreatic cancers are the fourth most common cause of
cancer-related deaths in the Western world. Approximately 5% to
10% of individuals with pancreatic cancer report a history of
pancreatic cancer in a close family member. In addition to this,
several known genetic syndromes have been shown to be
associated with an increased risk of pancreatic cancer. Thus,
germline mutations in the BRCA2, p16/CDKN2A, STK11, and
PRSS1, that are responsible for familial breast cancer, Familial
atypical multiple melanoma, Peutz-Jeghers and Familial pancre-
atitis, respectively, have been clearly associated with an increase
risk of pancreatic cancer [4]–[7]. Additionally, some studies have
described pancreatic cancer developing among individuals with
HNPCC [8], [9].
The PALB2 (partner and localizer of BRCA2) gene was
identified by searching for novel components of endogenous
BRCA2-containing complexes [10]. PALB2 supports BRCA2
stability and determines its localization in the nucleus after DNA
damage [10]. Relocation of PALB2 and BRCA2 to damaged
chromatin is regulated by BRCA1. These three proteins form a
complex in which PALB2 acts as a bridge between BRCA1 and
BRCA2 [11]. This complex is critical for the initiation of
homologous recombination in the DNA-damage response [11],
[12]. In cells depleted of PALB2 the DNA repair pathway
dependent on the BRCA1/2 is disrupted [10], [11]. Immediately
after PALB2 was discovered, evidence showed that it was also a
Fanconi anemia gene, known as FANCN [13], [14]. Biallelic
inactivation mutations in PALB2/FANCN cause Fanconi anemia
subtype N, characterized by a severe predisposition to pediatric
malignancies such as Wilms tumor, medulloblastoma, AML and
neuroblastoma [14]. Interestingly, the gene underlying the D1
subtype of Fanconi anemia, FANCD1 [15], was found to be BRCA2
and biallelic mutations in BRCA2/FANCD1 originate a phenotype
with high risk of childhood malignancies, very similar to that
produced by PALB2/FANCN biallelic mutations. This supports the
proposal that PALB2 is important for BRCA2 tumor suppression
activity [16].
As in other Fanconi anemia genes, monoallelic mutations in
PALB2 have been associated with increased breast cancer risk [3].
Thus, PALB2 monoallelic mutations have been identified in
approximately 1% of hereditary breast cancer families globally, as
summarized by Tischkowitz and Xia [16]. It has recently become
clear that the PALB2 gene should not only be considered as a
susceptibility gene for breast cancer but also for pancreatic cancer.
This pancreatic association was based on the identification of a
PALB2 mutation by exomic sequencing and the subsequent PALB2
analysis in additional familial pancreatic cancer patients that
revealed a prevalence of 3.1% [17]. A similar prevalence (3.7%)
was found by Slater et al [18] in European patients with familial
pancreatic cancer, whereby PALB2 carriers also had a history of
breast cancer.
Given these findings, we aimed to determine the prevalence of
PALB2 mutations in a Spanish population of BRCA1/BRCA2-
negative breast/ovarian cancer families with either a personal or
family history of pancreatic carcinoma.
Materials and Methods
Patients
Index cases from 132 BRCA1/BRCA2 mutation-negative
unrelated Spanish breast/ovarian cancer families with a personal
history of both breast and pancreatic cancer, or a family history
with pancreatic cancer cases, were screened for mutations within
the entire coding sequence and splicing sites as well as large
genomic rearrangements of PALB2 gene. Patient and family
characteristics are summarised in Table 1. Families were enrolled
from 11 different Spanish centres (Table S1). Ethical committee
approval and informed consent for all participants in the study
were obtained.
All index cases had been previously screened for point
mutations and large rearrangements in BRCA1 and BRCA2 genes.
All were found to be negative.
Mutation analysis of the PALB2 gene
Mutational analysis of PALB2 gene included the complete
coding sequencing and flanking intron-exon boundaries along with
the analysis of genomic rearrangements, as previously described by
Blanco et al [19].
Nomenclature and databases
Sequences used for PALB2 nomenclature were obtained from
the NCBI RefSeq database (NG_007406.1 for genomic,
NM_024675.3 for mRNA and NP_078951.2 for protein)
(http://www.ncbi.nlm.nih.gov). Standardized nomenclature was
reported considering the A of the ATG initiation codon of the
coding DNA Reference Sequence as nucleotide position +1.
Prediction of pathogenicity of splicing and missense
variants
Splicing predictions were performed with Splicing Sequences
Finder (SSF) (http://www.umd.be/searchSpliceSite.html), Max-
EntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_
scoreseq.html), NNSplice (http://www.fruitfly.org/seq_tools/
splice.html) and HumanSplicingFinder (HSF) (http://www.umd.
be/HSF/) algorithms through the Alamut- Mutation Interpreta-
tion Software v.1.54 (http://www.interactivebiosoftware.com/
alamut.html). Default thresholds were used for all the analyses.
Potential consequences of missense substitutions were obtained
using the prediction software PolyPhen-2 (Polymorphism Pheno-
typing-2, see http://genetics.bwh.harvard.edu/pph2/), SIFT
(Sorting Intolerant From Tolerant, see http://sift.jcvi.org/) and
Align-GVGD (Grantham score difference, see http://agvgd.iarc.
fr/) tools. Native alignments of each algorithm were used (see Text
S1 for a brief description of the tools).
CEU-population data from 1000 Genomes Project database
(http://www.1000genomes.org/) was used to obtain allelic
frequency of the identified variants in our samples.
Results
We sequenced all exons and splicing boundaries of PALB2 gene.
We also carried out MLPA analysis in 132 index cases from
BRCA1/BRCA2-negative families with breast and/or ovarian
cancer with either a personal or familial history of pancreatic
cancer. Two mutations were identified by sequencing analysis, the
PALB2 in Breast/Pancreatic Cancer Families
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nonsense c.1653T.A (p.Tyr551Stop) located at exon 4 with the
result of a premature stop codon, and the frameshift c.3362del
(p.Gly1121ValfsX3) in exon 13, which is predicted to generate a
translation-stop three codons downstream from the first affected
amino acid. The PALB2 truncating mutation c.1653T.A
(p.Tyr551Stop) was identified in a woman diagnosed with an
infiltrating ductal carcinoma (IDC), negative for estrogen receptor
(ER), progesterone receptor (PR) and HER2 at the age of 36. Her
mother had been diagnosed with breast cancer at 48 and with
pancreatic cancer at 72 years of age. Her maternal uncle had been
diagnosed with pancreatic cancer at 50 years of age (Figure 1A).
Unfortunately, it was not possible to obtain samples from family
members to confirm the mutation in the paternal branch of the
proband. The frameshift mutation in exon 13, c.3362del produces
a stop codon in position 1123 (p.Gly1121ValfsX3) that would
cause the loss of the 63 amino acids from the N-terminal PALB2
region. Other truncated mutations in the last codons of the gene
have already been described in breast/pancreatic cancer families
[3], [20]. It has been shown that residues 836 to 1186 of the
PALB2 protein are part of the WD40 repeats C-terminal domain
which associates with the N-terminus of BRCA2 [12], [13]. The
mutation c.3362del was identified in a woman diagnosed with
breast cancer at the age of 45. Likewise, the same mutation was
also detected in one of her sisters who was diagnosed with breast
cancer at the age of 43. Furthermore, they had another sister who
had been diagnosed with breast cancer; however, it was not
possible to carry out the genetic analysis. The three of them were
diagnosed with ER and PR positive infiltrating ductal carcinoma
(IDC). Moreover, two paternal aunts and also the paternal
grandfather were diagnosed with pancreatic cancer at the ages of
81, 50 and 44, respectively. We could not, unfortunately, confirm
the origin of the mutation in the maternal branch. Other types of
Table 1. BRCA1/BRCA2 mutation-negative Spanish high risk breast/ovarian cancer families with pancreatic cancer cases.
Type of case N6 of cases (n=132)
Mean age at cancer
diagnosis Additional family history
Personal history of BC and PC 3 BC:43.6 PC in FDR:0
PC:44 PC in SDR:2
BC in FDR:0
BC in SDR:1
Personal history of PC and familiar
history of BC and PC
4 PC:65 PC in FDR:1
PC in FDR: 50 PC in SDR:0
BC in FDR:4 (1BiBC)
BC in SDR:1
Personal history of OC and familiar history of PC 9 (1BiOC) OC:43.6 PC in FDR:3
PC in FDR: 71.5 PC in SDR:7
PC in SDR: 64.7 BC in FDR:1
BC in SDR:2 (1 BiBC)
OC in FDR:2
OC in SDR:2
Personal history of PrC and familiar history of BC and PC 2 PrC:54.5 PC in FDR:1
PC in FDR: 61 PC in SDR:2
PC in SDR: 77 BC in FDR:2
BC in SDR:2 (1 BiBC)
OC in SDR:1
Personal history of BC and
familiar history of PC
BC iagnosed ,50 92 (13BiBC (1+leukemia, 1+melanoma;
1+OC), 1 MBC, 1+CCR
BC:39.2 PC in FDR:25 (1+BC)
PC in FDR:58.8 PC in SDR:50
PC IN SDR: 63.8 BC in FDR:31 (2 BiBC)
BC in SDR:26 (1 BiBC, 1 MBC)
OC in FDR:1
OC in SDR:4
BC diagnosed .50 22 (4 BiBC, 1MBC, 1+OC, 1+endometrium)BC:58.6 PC in FDR:9 (1+BC)
PC in FDR:64.1 PC in SDR:12 (1+BC)
PC in SDR:65.7 BC in FDR:15 (1 BiBC, 1 MBC, 1+PC)
BC in SDR:15
OC in FDR:1
OC in SDR:1
BC: Breast cancer; PC: Pancreatic cancer; OC: Ovarian cancer; BiOC: Bilateral Ovarian cancer; PrC: Prostate cancer; MBC: Male Breast cancer; BiBC: Bilateral Breast Cancer;
CCR: Colorectal cancer; FDR: First degree relative; SDR: Second degree relative.
doi:10.1371/journal.pone.0067538.t001
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cancer present in the family were skin, stomach and CNS in
paternal aunts (Figure 1B).
In addition to these two mutations, sequence analysis revealed
another 21 different PALB2 variants and polymorphims (Table 2),
one in the 59UTR region, 4 in introns and 16 in exons (12
missense and 4 silent coding variants). From the total number of
variants identified, seven were novel (c.110G.A (p.Arg37His),
c.212-180T.G, c.232G.A (p.Val78Ile), c.262C.T
(p.Leu88Phe), c.1431T.C (p. = ), c.2587-59T.C, c.2837C.G
(p.Ala946Gly)) and observed only once in our samples, whereas
the other variants had been previously reported [3], [19], [21],
[22].
The results of bioinformatic predictions for intronic and
missense variants are represented in Table 3. Four of the missense
variants, c.1010T.C (p.Leu337Ser), c.2816T.G (p.Leu939Trp),
c.2837C.G (p.Ala946Gly) and c.2993G.A (p.Gly998Gln), were
predicted to likely affect PALB2 protein function by all the tested
algorithms. Variants c.2816T.G (p.Leu939Trp) and c.2837C.G
(p.Ala946Gly) are not present in CEU 1000 Genome Project
samples, whereas c.1010T.C (p.Leu337Ser) and c.2993G.A
(p.Gly998Gln), have a 2% frequency in CEU population (Table 2).
For variant c.2816T.G (p.Leu939Trp), a similar frequency in
controls and cases was observed [22]–[][24]. For the missense
variant c.110 G.A (p.Arg37His) two of the three prediction
programs considered the variant as deleterious, whereas only one
prediction tool considered variants c.262 C.T (p.Leu88Phe),
c.2014 G.C (p.Glu672Gln), c.2590 C.T (p.Pro864Ser) and
2794 G.A (Val932Met) as deleterious (see Table 3). The
bioinformatic splicing analyses showed consensus site score
variations for variants c.110 G.A (p.Arg37His) (three programs),
c.2837C.G (p.Ala946Gly) (two programs) and c.2993G.A
(p.Gly998Gln) (one program). A destruction of a cryptic splice
site was predicted for variants c.-47G.A and c.2794G.A
(p.Val932Met) by three and two programs, respectively, as well
as an increase in the score of a cryptic sites by all programs for the
variant c.2794G.A (p.Val932Met) and by two programs for the
variant c.2590C.T (p.Pro864Ser).
Discussion
Mutations in PALB2 gene were originally associated with an
increased risk for breast cancer and later, with pancreatic cancer.
We analyzed a large series of hereditary breast/pancreatic cancer
families analysed for PALB2mutations. We identified two germline
truncating mutations, the nonsense c.1653T.A (p.Tyr551Stop)
located at exon 4 and the novel frameshift mutation c.3362del
(p.Gly1121ValfsX3) in exon 13. These mutations were considered
to be pathogenic, since they all create a stop codon that is
predicted to cause a truncation of the PALB2 protein. The
nonsense mutation c.1653T.A (p.Tyr551Stop) had been previ-
ously reported in a Fanconi anemia patient as well as in a familial
breast cancer case [13], [25]. Truncating mutations in PALB2 are
rare in individuals without cancer. In fact, they had not been
identified in 1084 healthy individuals analysed [3]. In our series,
c.1653T.A (p.Tyr551Stop) and c.3362del (p.Gly1121ValfsX3)
were identified in index cases diagnosed with breast cancer under
50 years of age and at least one first degree relative diagnosed with
pancreatic cancer. No ovarian cancer was present in these families.
Considering these two PALB2 variants as causal mutations, the
prevalence of PALB2 mutation in our BRCA1/BRCA2 breast and
pancreatic cancer series is 1.5% (2/132). Previous studies of
Figure 1. Pedigrees of the families carrying the mutations. a) c.1653T.A (p.Tyr551Stop); b) c.3362del (p.Glu1121ValfsX3). Cancer diagnoses
are indicated in affected patients; in brackets the age at diagnosis or exitus. The arrow indicates the index case analyzed. BC breast cancer, PC
Pancreatic Cancer, CCR Colorectal cancer, CNS central nervous system cancer.
doi:10.1371/journal.pone.0067538.g001
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breast/pancreatic cancer families have described prevalences from
0% (77 families analysed in Stadler et al [26], 45 in Adank et al
[27], 29 in Guiorzo et al [28] and 28 in Harinck et al [29]), 2.1%
(Hofstatter et al [24], 2 mutations in 94 families), to 4.8%
(Peterlongo et al [20], 3 mutations in 62 families) reviewed in
Table 4. Considering these studies with our data, the global
prevalence of PALB2 mutation in breast/pancreatic cancer
families is 1.5% (7 mutations in 467 families).
We recently, estimated a PALB2 mutation prevalence of 0.75%
for Spanish breast/ovarian cancer families with at least one male
breast cancer case [19]. Although we identified twice as many
carriers in families with pancreatic cancer cases than in families
with male breast cancer cases, both prevalences are similar to the
1% reported for families with breast cancer unselected for other
cancers [3], [30], [31]. Importantly, for most of the breast/
pancreatic cancer series analysed, index cases were breast cancers.
Similarly, in our study only 7 from the 132 index cases were
pancreatic cancer. The selection of index cases could therefore be
introducing a bias in the estimate of the prevalence of PALB2
mutations in these families.
The selection of a gene to be included in a routine genetic test
would be, in part, based on the risk it confers. However, the risk
associated with deleterious mutations in genes like PALB2 is not
easily determined since deleterious alleles are extremely rare in the
population, and the number of mutation carriers in published
studies are small [32]. Mutations in PALB2 gene were originally
associated with a moderate (2–3 fold) increase risk for breast
cancer [3]. As higher risks were increasingly suggested, at least for
specific mutations [33], [34], the inclusion of this gene in
hereditary breast cancer tests would be justified.
In our study both breast tumors from our PALB2 families were
IDC, even though one of them had a triple negative phenotype
(c.1653T.A, p.Tyr551Stop), while the other was ER+ and PR+
(c.3362del, p.Gly1121ValfsX3). It has been shown that some
PALB2-associated breast cancers display a more aggressive tumor
phenotype, including triple-negative disease, higher tumor grade
and higher Ki67 expression [35]. Thus, tumors of the 1592delT
PALB2 mutation carriers presented triple negative phenotype
more often (54.5%, P,0.0001) than those of other familial (12.2%)
or sporadic (9.4%) breast cancer patients [35]. In fact, nearly 40%
of the PALB2-associated breast tumors identified to date displaied
a triple-negative phenotype, regardless of the specific PALB2
mutation [16]. This representation of triple negative tumors, more
akin to BRCA1- than BRCA2-related tumors, could be related to
Table 2. PALB2 sequence variants identified in 132 Spanish breast/ovarian cancer families with pancreatic cancer cases.
CASE POPULATION
CONTROL
POPULATION
GENOTYPES
ALLELIC FREQUENCY
(%)b 1000 GENOMES
NUCLEOTIDE
CHANGEa PROTEIN CHANGE Name of SNP AA AB BB A (A%) B (B%) A% B%
59 upstream
sequence
c.-47G.A - rs8053188 127 5 0 259(98.1) 5(1.9) 98 2
EXON 3 c.110G.A p.Arg37His rs202194596 131 1 0 263(99.6) 1(0.4) 100 0
INTRON 3 c.212-180T.G - - 131 1 0 263(99.6) 1(0.4)
c.212-58A.C - rs80291632 123 9 0 255 (96.6) 9(3.4) 96 4
EXON 4 c.232G.A p.Val78Ile - 131 1 0 263(99.6) 1(0.4)
c.262C.T p.Leu88Phe - 131 1 0 263(99.6) 1(0.4)
c.656A.G p.Asp219Gly rs45594034 131 1 0 263(99.6) 1(0.4) 100 0
c.1010T.C p.Leu337Ser rs45494092 131 1 0 263(99.6) 1(0.4) 98 2
c.1194G.A p. = rs61755173 130 2 0 262(99.2) 2(0.8) 100 0
c.1431T.C p. = - 131 1 0 263(99.6) 1(0.4)
c.1572A.G p. = rs45472400 131 1 0 263(99.6) 1(0.4) 100 0
c.1653T.A p.Tyr551Stop rs118203997 131 1 0 263(99.6) 1(0.4)
c.1676A.G p.Gln559Arg rs152451 105 24 3 234(88.6) 30(11.4) 90 10
EXON 5 c.2014G.C p.Glu672Gln rs45532440 122 10 0 254(96.2) 10(3.8) 96 4
INTRON 6 c.2586+58C.T - rs249954 90 37 5 217(82.2) 47(17.8) 79 21
c.2587-59T.C - - 131 1 0 263(99.6) 1(0.4)
EXON 7 c.2590C.T p.Pro864Ser rs45568339 129 3 0 261(98.9) 3(1.1) 100 0
EXON 8 c.2794G.A p.Val932Met rs45624036 131 1 0 263(99.6) 1(0.4) 99 1
c.2816T.G p.Leu939Trp rs45478192 131 1 0 263(99.6) 1(0.4) 100 0
EXON 9 c.2837C.G p.Ala946Gly - 131 1 0 263(99.6) 1(0.4)
c.2993G.A p.Gly998Gln rs45551636 125 7 0 257(97.3) 7(2.7) 98 2
EXON 12 c.3300T.G p. = rs45516100 123 9 0 255 (96.6) 9(3.4) 96 4
EXON 13 c.3362del p.Gly1121ValfsX3 - 131 1 0 263(99.6) 1(0.4)
aIn bold variants not previously reported.
bAllelic frequency is the percentage of n/N, where n is the number of minor alleles and N is the total number of alleles.
doi:10.1371/journal.pone.0067538.t002
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the nature of the interaction and/or certain functional similarities
between PALB2 and BRCA1 [11], [12], or a direct transcriptional
activation of the estrogen receptor by PALB2 as has been shown for
BRCA1 [36]. However, larger numbers of PALB2-related tumors
will need to be studied before any firm conclusions can be drawn.
As shown in Table 3, different prediction tools gave contradic-
tory results. For instance, missense variants c.656 A.G (p.As-
p219Gly) and c.2590 C.T (p.Pro864Ser) were predicted as C65
(likely to be pathogenic) by A-GVGD and as Benign and
Tolerated by Polyphen and Sift. Prediction of individual variants
can be sensitive to the aligment used; both the number and type of
orthologues aligned at the mutation site can affect prediction of
pathogenicity [37]. Since we used default alignments for each tool,
we cannot rule out that the different outcomes we have for these
variants is related to this. However, an optimum alignment is
difficult to identify and is likely to vary depending on the variant
tested [37]. It has been previously shown that the accuracy of the
result improves when multiple algorithms give the same prediction
[38]. Considering this as well as such consensus predictions for all
tools, four of the missense variants identified in our patients were
classified as probably deleterious (Table 3). Three of them
(c.1010C.T, c.2816T.G and c.2993G.A), had not been
previously related with breast cancer risk [3], [19], [21], [24].
Although a recent study did not showed evidence of the influence
of rare PALB2 missense mutations and breast cancer risk [34], we
think that multifactorial analysis incorporating different approach-
es to obtain a final pathogenic probability, are required to assess
the implication of each of these missense PALB2 variants.
Results from the in silico splicing analysis show three variants
predicted to modify the scores for the canonical AG/GT
dinucleotides, and three other variants that would modify the
score of cryptic splice sites. Recently published guidelines for
splicing analysis [39] indicate that only variants located in the
consensus sites described by Cartegni et al [40], 11 bases for the 59
site (from the 3 last exonic to the 8 first intronic bases) and 14 bases
for the 39 site (from the 12 last intronic to the first 2 exonic bases),
would have reliable predictions with these bioinformatic tools [39].
In our study, this would mean that the unique reliable prediction is
for variant c.110 G.A (p.Arg37His), at the second exonic base from
the 39 site. However, the reduction in the score predicted by the
algorithms, all lower than 10%, and the absence of variations near
cryptic splice sites would suggest that c.110 G.A (p.Arg37His) is
not a variant producing a major impact in splicing process. The
RNA analysis of the variant confirmed this prediction (Table 3).
Conclusions
In summary, we found that PALB2 mutations occur with a
prevalence of 1.5% in a population of BRCA1/2-negative breast
cancer patients specifically selected from a personal and/or familiar
history of pancreatic cancer. This is not much different from the
prevalence described for families not selected for the presence of
pancreatic cancer. However, we cannot rule out a higher PALB2
prevalence in series with more pancreatic cancer index cases.
PALB2 mutations seem to explain only a small fraction of the
clustering of both pancreatic and breast cancer. It is therefore, crucial
that future research aims to identify other gene(s) that are involved in
the development of familiar breast/pancreatic cancer cases.
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Text S1 This document summarizes the meanings of
scores of bioinformatic programs used.
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Table 4. Overview of literature on role of PALB2 mutations in FPC and in BC families affected by PC (BC-PC families).
STUDY COUNTRY/ETHNICITY PATIENTS PALB2 MUTATIONS FAMILIAR HISTORY
Jones et al [17] USA 96 FPC families c.172-175delTTGT: 1(PC)
c.3116delA: 1(PC+PrC)
c.3256C.T: 1(PC+BC)
c.172-175delTTGT: family history of BC
c.3116delA: family history of BC-PC
c.3256C.T: family history of BC-PC
Tischkowitz et al [23] Canada 254 PC (114 sporadic,
80 FPC, 21 FPC with breast/
ovary cases; 39 sporadic
PC with breast/ovary cases)
6.7-kb germline deletion
(exons12–13): 1 (BC+PC)
6.7-kb germline deletion (exons12–13):
family history of PC
Hofstatter et al [25] USA 94 BC-PC families c.2962C.T: 1BC(49)
c.3549C.CA: 1BC(43)
c.2962C.T: family history of BC-PC
c.3549C.CA: family history of BC-PC
Slater et al [18] Europe 81 FPC families c.1240C.T: 1(PC) c.508-
509delAG: 1(PC)
c.3116delA: 1(PC)
c.1240C.T: family history of BC-PC c.508-
509delAG: family history of BC-PC
c.3116delA: family history of BC-PC
Adank et al [28] The Netherlands 45 BC-PC families
(all index cases BC)
Peterlongo et al [21] Italy 62 BC-PC families c.72delG: 1(BC) c.1027C.T:
1(BC) c.3497delG: 1(BC)
c.72delG: family history of BC-PC
c.1027C.T: family history of BC-PC
c.3497delG: family history of BC-PC
Stadler et al [27] USA 77 BC-PC families
Guiorzo et al [29] Italy 29 BC-PC famililes
Harinck et al [30] The Netherlands 56 (28 FPC families as
28 BC-PC families)
Current study Spain 132 BC-PC families c.1653T.A: 1(BC)
c.3362del: 1(BC)
c.1653T.A: family history of BC-PC
c.3362delG: family history of BC-PC
BC (breast cancer); PC (pancreatic cancer); FPC (familial pancreatic cancer); PrC (prostate cancer).
doi:10.1371/journal.pone.0067538.t004
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